January 8, 2024

Wellness solutions that improve employee health and lower costs

85% of healthcare costs stem from preventable chronic health conditions.1 Progressive companies are always looking for ways to improve employee outcomes and reduce soaring costs beyond traditional wellness programs. Our friends at Shortlister hosted Emily Roberts, executive director of client success at Labcorp, and Colin Fenn, enterprise sales leader at Labcorp, to discuss how a comprehensive suite of on-site and at-home test options, personalized one-on-one employee health coaching, an interactive online platform, and robust analytical tools support population health management strategies and empower employees to enhance their overall health. 
<span>Getting SMARTer about New Year’s resolutions</span>
January 8, 2024

Getting SMARTer about New Year’s resolutions

Welcome to 2024! Many people approach the new year with excitement and anticipation for the possibilities and opportunities ahead. With the new year comes one of the most popular times and ways to make big changes in our lives—New Year’s resolutions. 
December 21, 2023

Precision Medicine World Conference (PMWC) 2024

Join us January 24 - 26, in Silicon Valley, California at the Santa Clara Convention Center for PMWC 2024.


Panel Discussion:  
Track 3: Oncology Applications Track
January 24 9.00 A.M.-4.45 P.M.

Collaborative Frontiers: Transforming Cancer Care Access and Patient Outcomes (PANEL)

February 1, 2023

Expanded PersistenceT™ panels for deeper analysis of CAR T persistence

Adoptive cell therapy (ACT) with T-cells reprogrammed to express chimeric antigen receptors (CAR T-cells) bind specific antigens on the surface of cancer cells and trigger a cytotoxic response. CAR T-cell therapies have been successful in patients with hematological malignancies; however, patients remain at risk of relapse due to short-term persistence or non-expansion of CAR T-cells.1,2 This requirement for persistence is more evident in solid tumors as the hostile tumor microenvironment induces T-cell exhaustion.3,4 Studies have found that genomic and phenotypic features of CAR T-cells were major determinants of their persistence. Clinical results have shown that stemness and a memory-cell-like phenotype can promote sustained in vivo persistence of adoptively transferred CAR T-cells.3,4